alt

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013)

September 10-13, 2013, Denver

Back Home Content Conference Coverage

ICAAC 2013: Treatment of HCV Genotypes 2/3 in HIV/HCV Coinfected People

HIV/HCV coinfected patients, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV negative people to pegylated interferon plus ribavirin after taking into account other factors associated with poor treatment response, according to an Italian study presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. Advanced liver fibrosis was common in the coinfected group, supporting the need for early treatment.

alt

Read more:

ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected

Effective interferon-based therapy that produces sustained virological response (SVR) led to significant reductions in liver decompensation, HIV disease progression, and both overall and liver-related mortality among HIV/HCV coinfected patients, according to a presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.  

alt

Read more:

ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding

An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.

alt

Read more: